Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.
- Author:
Chrysoula BOUTARI
1
;
Nikolaos PERAKAKIS
;
Christos Socrates MANTZOROS
Author Information
- Publication Type:Review
- Keywords: Non-alcoholic fatty liver disease; Adipokines; Adiponectin; Leptin; Resistin; Nicotinamide phosphoribosyltra; Chemerin; Retinol-binding protein 4
- MeSH: Adipokines*; Adiponectin; Adipose Tissue; Cytokines; Hand; Leptin; Liver; Liver Diseases; Nicotinamide Phosphoribosyltransferase; Non-alcoholic Fatty Liver Disease*; Obesity; Resistin; Thiazolidinediones
- From:Endocrinology and Metabolism 2018;33(1):33-43
- CountryRepublic of Korea
- Language:English
- Abstract: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting 30% of the general population and 40% to 70% of obese individuals. Adipose tissue plays a crucial role in its pathogenesis, as it produces and secretes pro- and anti-inflammatory cytokines called adipokines. Adiponectin and leptin have well-determined actions in terms of NAFLD pathophysiology. Adiponectin deficiency is associated with a pro-inflammatory condition, as it is observed in obesity and other metabolic disorders. On the other hand, increased leptin levels, above the normal levels, act as a pro-inflammatory stimulus. Regarding other adipokines (resistin, visfatin, chemerin, retinol-binding protein 4, irisin), data about their contribution to NAFLD pathogenesis and progression are inconclusive. In addition, pharmacological agents like thiazolidinediones (pioglitazone and rosiglitazone), that are used in the management of NAFLD exert favourable effects on adipokine levels, which in turn may contribute to the improvement of liver function. This review summarizes the current knowledge and developments in the association between adipokines and NAFLD and discusses possible therapeutic implications targeting the modulation of adipokine levels as a potential tool for the treatment of NAFLD.
